Goserrelina Teva (Goserelin)

Goserrelina Teva is indicated for several hormone‑sensitive diseases where reduction of testosterone or estrogen levels is desired.

• Treatment of advanced prostate cancer in men.
• Management of hormone‑responsive breast cancer in pre‑menopausal women.
• Therapy for endometriosis to reduce pelvic pain and lesion growth.
• Reduction of uterine fibroid size and associated bleeding.
• Adjunctive use in assisted reproduction protocols to control ovarian stimulation.

The medication may be prescribed as part of a multidisciplinary treatment plan and is typically given by a healthcare professional experienced in hormone therapy.

Side‑effect profiles for Goserrelina Teva reflect its hormonal suppression and can vary in frequency and severity.

Common

• Hot flashes and sweating.
• Decreased libido or sexual dysfunction.
• Mood changes such as irritability or depression.
• Injection‑site reactions including pain, erythema, or swelling.
• Fatigue or general weakness.

Serious

• Bone mineral density loss leading to osteoporosis.
• Cardiovascular events such as hypertension or thromboembolism.
• Severe allergic reactions (anaphylaxis, angioedema).

Patients should report any new or worsening symptoms to their clinician promptly.

Before starting Goserrelina Teva, clinicians assess several safety considerations to minimize risks associated with long‑term hormone suppression.

• Evaluate bone health; consider calcium and vitamin D supplementation.
• Review cardiovascular risk factors such as hypertension, hyperlipidemia, or smoking.
• Assess liver and kidney function, especially in patients with chronic disease.
• Discuss potential impact on fertility and consider sperm or oocyte preservation.
• Monitor for signs of depression or mood disorders during therapy.
• Use caution in patients with a history of thromboembolic events.

Goserrelina Teva can alter the metabolism or effectiveness of other medicines; certain combinations should be avoided while others require close monitoring.

Avoid

• Concurrent use with estrogen‑containing hormone replacement therapy, which may counteract the drug’s effect.
• Combining with other GnRH agonists or antagonists, leading to excessive hormone suppression.

Use with caution

• Anticoagulants, because changes in hormone levels can affect clotting risk.
• Corticosteroids, which may increase bone loss when used together.
• Chemotherapy agents, requiring timing adjustments to avoid overlapping toxicities.
• Bisphosphonates or denosumab, to manage potential osteoporosis.